Management of IgA nephropathy has entered a new era with the arrival of advanced therapies. While SGLT2 inhibitors and RAS inhibitors remain foundational, many patients still face the threat of kidney failure. This recent crossover trial provides exciting data on the role of Atrasentan in IgA nephropathy as an adjunct treatment. Consequently, by targeting specific pathways, this drug offers additional hope for patients with persistent proteinuria.

Improving Outcomes with Atrasentan in IgA Nephropathy

The study involved 54 adults with IgA nephropathy who were already receiving stable doses of guideline-recommended therapies. In this study, researchers compared the efficacy of 0.75 mg daily atrasentan against a placebo over a 12-week period. Consequently, the results showed a striking difference. Atrasentan led to a 25.3% reduction in the urinary protein-to-creatinine ratio compared to the placebo. Moreover, patients experienced a total 48.1% drop from their baseline levels. These findings clearly indicate that adding atrasentan provides significant clinical benefits beyond current standard treatments.

Safety and Clinical Implications

Safety remains a primary concern when combining multiple potent drugs. Fortunately, the trial demonstrated that the combination was well-tolerated. Specifically, there were no reported cases of heart failure or serious edema. Because SGLT2 inhibitors have diuretic properties, they might mitigate the fluid retention typically associated with endothelin receptor antagonists. Furthermore, most adverse events were mild or moderate in severity. Therefore, clinicians can consider this combination as a safe strategy to further reduce residual risk in high-risk patients.

Conclusion

In summary, this trial confirms that atrasentan is an effective tool for lowering proteinuria. When integrated into a regimen of RAS and SGLT2 inhibitors, it produces a clinically meaningful impact. Consequently, this multi-targeted approach could become the new standard for preserving kidney function in IgA nephropathy.

Frequently Asked Questions

How does atrasentan provide extra protection in IgA nephropathy?

Atrasentan acts as a selective endothelin-A receptor antagonist. By blocking this pathway, it reduces glomerular pressure and inflammation, which are not fully addressed by SGLT2 or RAS inhibitors alone.

Are the side effects of atrasentan manageable?

Yes, the safety profile is encouraging. The most common side effects are mild, and the risk of significant fluid retention appears low, especially when used with SGLT2 inhibitors.

What is the expected reduction in proteinuria with this combination?

Clinical data showed that adding atrasentan to existing therapy can lead to an additional 25.3% reduction in proteinuria compared to standard care alone.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Heerspink HJL et al. Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial. J Am Soc Nephrol. 2026 Mar 29. doi: 10.1681/ASN.0000001076. PMID: 41904616.


2. Heerspink HJL, et al. Atrasentan in Patients with IgA Nephropathy. N Engl J Med. 2025 Feb 6;392(6):544-554.


3. Novartis. Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy. Press Release. February 13, 2026.